28 March 2023

ASX Release

Notice under Section 708A of the Corporations Act

This notice is given by **Firebrick Pharma Limited** (**Issuer** or **Company**) (**ASX:FRE**) under section 708A(5)(e) of the Corporations Act 2001 (Cth) ("**Act**").

The Company has today issued 372,531 ordinary fully paid shares upon exercise of unlisted options at an exercise price of $0.0217 per ordinary fully paid share ("**Issued Shares**")

In accordance with section 708A(5)(e) of the Act, the Company gives notice that:

1. the Issued Shares were issued without disclosure to investors under Part 6D.2 of the Act;

2. as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act, as they apply to the Company and section 674 of the Act; and

3. as at the date of this notice there is no information that is 'excluded' information within the meanings of section 708A(7) and 708A(8) of the Act, being information:

    a) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules;

    b) that investors and their professional advisers would reasonably require for the purposes of making and informed assessment of:

        i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or

        ii. the rights and liabilities attaching to the Securities.

This announcement has been authorised for release by the Board of Firebrick Pharma Limited.

Yours faithfully

Stephen Buckley

Company Secretary

About Firebrick Pharma

Firebrick is a pharmaceutical company founded with the mission to commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company owns numerous granted and pending patents, including a core patent family that covers the use of intranasal povidone-iodine for the treatment and prevention of the common cold and a second patent family covering the prevention of pandemic viral diseases, including COVID-19. The Company also has a third patent family covering the Nasodine formulation, which has been granted in Australia. Firebrick is completing two major clinical trials: A Phase 2 trial of Nasodine in COVID-19 and a Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals. Positive Phase 3 trial results will also be important for securing regulatory approvals and partnerships in major markets outside Australia.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com